You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNabilone
Accession NumberDB00486  (APRD01127)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionNabilone is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It is a synthetic cannabinoid, which mimics the main ingredient of marijuana (THC) but it has more predictable side effects and causes no or minimal euphoria. Nabilone is not derived from the cannabis plant as is dronabinol. In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS. Although it doesn't have the official indication (except in Mexico), nabilone is widely used as an adjunct therapy for chronic pain management. Numerous trials and case studies have demonstrate various benefits for condition such as fibromyalgia and multiple scerosis. Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers ("trans").
Structure
Thumb
Synonyms
Cesamet
Nabilon
Nabilona
Nabilone
Nabilonum
External Identifiers
  • Cpd 109514
  • LY 109 514
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Nabilonecapsule0.5 mgoralActavis Pharma Company2012-10-02Not applicableCanada
Act Nabilonecapsule1 mgoralActavis Pharma Company2012-10-02Not applicableCanada
Cesametcapsule1 mg/1oralMeda Pharmaceuticals Inc.2010-03-01Not applicableUs
Cesametcapsule0.25 mgoralValeant Canada Lp Valeant Canada S.E.C.2008-09-12Not applicableCanada
Cesametcapsule1 mg/1oralValeant Pharmaceuticals North America2009-11-01Not applicableUs
Cesametcapsule1 mgoralValeant Canada Lp Valeant Canada S.E.C.1982-12-31Not applicableCanada
Cesametcapsule0.5 mgoralValeant Canada Lp Valeant Canada S.E.C.2004-09-16Not applicableCanada
PMS-nabilonecapsule0.25 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-nabilonecapsule0.5 mgoralPharmascience Inc2012-03-26Not applicableCanada
PMS-nabilonecapsule1.0 mgoralPharmascience Inc2012-03-26Not applicableCanada
Ran-nabilonecapsule1 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Ran-nabilonecapsule0.25 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Ran-nabilonecapsule0.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Teva-nabilonecapsule1.0 mgoralTeva Canada Limited2012-05-23Not applicableCanada
Teva-nabilonecapsule0.25 mgoralTeva Canada Limited2013-05-27Not applicableCanada
Teva-nabilonecapsule0.5 mgoralTeva Canada Limited2012-05-23Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nabilonecapsule0.25 mgoralApotex IncNot applicableNot applicableCanada
Apo-nabilonecapsule0.5 mgoralApotex IncNot applicableNot applicableCanada
Apo-nabilonecapsule1 mgoralApotex IncNot applicableNot applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NabiloneMeda
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2N4O9L084N
CAS number51022-71-0
WeightAverage: 372.5408
Monoisotopic: 372.266445018
Chemical FormulaC24H36O3
InChI KeyInChIKey=GECBBEABIDMGGL-RTBURBONSA-N
InChI
InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1
IUPAC Name
(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6H,6aH,7H,8H,9H,10H,10aH-benzo[c]isochromen-9-one
SMILES
[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthopyranones. These are compounds containing a naphthopyran skeleton where a ring carbon bears a carboxylic acid group. Naphthtopyran is made up of the pyran ring fused to a naphthalene ring system.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthopyrans
Sub ClassNaphthopyranones
Direct ParentNaphthopyranones
Alternative Parents
Substituents
  • Naphthopyranone
  • 2,2-dimethyl-1-benzopyran
  • 1-benzopyran
  • Benzopyran
  • Chromane
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Cyclic ketone
  • Ketone
  • Oxacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed for the control of nausea and vomiting, caused by chemotherapeutic agents used in the treatment of cancer, in patients who have failed to respond adequately to conventional antiemetic treatments.
PharmacodynamicsNabilone is a cannabinoid with therapeutic uses. It is an analog of dronabinol (also known as tetrahydrocannabinol or THC), the psychoactive ingredient in cannabis. It is reserved for use in individuals who do not respond to the more commonly used anti-emetics. This is mainly because cannabinoids have potential adverse effects similar to that of cannabis and may cause changes in mood and behaviour.
Mechanism of actionThe mode of action of nabilone has been studied in cats and dogs. Although its anti-emetic action is not yet fully understood, it is apparent that there are a number of points in the control systems of the body at which Nabilone could block the emetic mechanism. It is likely that nabilone exerts its actions via binding to the cannabinoid receptors.
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract following oral administration.
Volume of distribution
  • 12.5 L/kg
Protein bindingNot Available
Metabolism

Hepatic. Two metabolic pathways have been suggested. The major pathway probably involves the direct oxidation of Nabilone to produce hydroxylic and carboxylic analogues. These compounds are thought to account for the remaining plasma radioactivity when carbinol metabolites have been extracted.

Route of eliminationThe route and rate of the elimination of nabilone and its metabolites are similar to those observed with other cannabinoids, including delta-9-THC (dronabinol). Therefore, it appears that the major excretory pathway is the biliary system.
Half life2 hours, with metabolites around 35 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include difficulty in breathing, hallucinations, mental changes (severe), nervousness or anxiety (severe). Monkeys treated with Nabilone at doses as high as 2mg/kg/day for a year experienced no significant adverse events. This result contrasts with the finding in a planned 1-year dog study that was prematurely terminated because of deaths associated with convulsions in dogs receiving as little as 0.5mg/kg/day. The earliest deaths, however, occurred at 56 days in dogs receiving 2mg/kg/day. The unusual vulnerability of the dog is not understood; it is hypothesised, however, that the explanation lies in the fact that the dog differs markedly from other species (including humans) in its metabolism of Nabilone.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9575
Caco-2 permeable+0.7787
P-glycoprotein substrateSubstrate0.8103
P-glycoprotein inhibitor INon-inhibitor0.7926
P-glycoprotein inhibitor IIInhibitor0.6054
Renal organic cation transporterNon-inhibitor0.836
CYP450 2C9 substrateNon-substrate0.7385
CYP450 2D6 substrateNon-substrate0.8433
CYP450 3A4 substrateSubstrate0.6842
CYP450 1A2 substrateNon-inhibitor0.6601
CYP450 2C9 inhibitorNon-inhibitor0.714
CYP450 2D6 inhibitorNon-inhibitor0.9059
CYP450 2C19 inhibitorNon-inhibitor0.6521
CYP450 3A4 inhibitorNon-inhibitor0.8654
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7642
Ames testNon AMES toxic0.8337
CarcinogenicityNon-carcinogens0.8598
BiodegradationNot ready biodegradable0.9948
Rat acute toxicity2.5397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9159
hERG inhibition (predictor II)Non-inhibitor0.7654
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Meda pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral0.25 mg
Capsuleoral0.5 mg
Capsuleoral1 mg/1
Capsuleoral1 mg
Capsuleoral1.0 mg
Prices
Unit descriptionCostUnit
Cesamet 1 mg capsule13.99USD capsule
Cesamet 0.5 mg Capsule3.49USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000493 mg/mLALOGPS
logP7.5ALOGPS
logP6.36ChemAxon
logS-5.9ALOGPS
pKa (Strongest Acidic)9.33ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.2 m3·mol-1ChemAxon
Polarizability44.91 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Soukop M, Kaye SB: A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol. 1988 Apr;24(4):685-9. [PubMed:2838294 ]
  2. Niiranen A, Mattson K: Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol. 1987 Aug;10(4):325-9. [PubMed:3039831 ]
  3. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979 Jun 7;300(23):1295-7. [PubMed:375088 ]
  4. Einhorn LH, Nagy C, Furnas B, Williams SD: Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981 Aug-Sep;21(8-9 Suppl):64S-69S. [PubMed:6271844 ]
External Links
ATC CodesA04AD11
AHFS Codes
  • 56:22.92
PDB EntriesNot Available
FDA labelDownload (94.9 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Nabilone.
AcebutololNabilone may increase the tachycardic activities of Acebutolol.
AcepromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Nabilone.
AceprometazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Nabilone.
AclidiniumAclidinium may increase the tachycardic activities of Nabilone.
adipiplonNabilone may increase the central nervous system depressant (CNS depressant) activities of adipiplon.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Nabilone.
AgomelatineNabilone may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nabilone.
AlfaxaloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Nabilone.
AlfentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Nabilone.
AlphacetylmethadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Nabilone.
AlprazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nabilone.
AmisulprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Nabilone.
AmitriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nabilone.
AmobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nabilone.
AmoxapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nabilone.
AmperozideNabilone may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Nabilone.
AmphetamineNabilone may increase the tachycardic activities of Amphetamine.
Anisotropine MethylbromideAnisotropine Methylbromide may increase the tachycardic activities of Nabilone.
AripiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nabilone.
ArticaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Articaine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Nabilone.
AsenapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Nabilone.
Atracurium besylateAtracurium besylate may increase the tachycardic activities of Nabilone.
AtropineAtropine may increase the tachycardic activities of Nabilone.
AzaperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Nabilone.
AzelastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nabilone.
BaclofenNabilone may increase the central nervous system depressant (CNS depressant) activities of Baclofen.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Nabilone.
BarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Nabilone.
BenactyzineBenactyzine may increase the tachycardic activities of Nabilone.
BenzatropineBenzatropine may increase the tachycardic activities of Nabilone.
BenzocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Nabilone.
BenzphetamineNabilone may increase the tachycardic activities of Benzphetamine.
Benzyl alcoholNabilone may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Nabilone.
BiperidenBiperiden may increase the tachycardic activities of Nabilone.
BrexpiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Nabilone.
BrimonidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
BromazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nabilone.
BrompheniramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Nabilone.
BrotizolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Nabilone.
BupivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nabilone.
BuprenorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nabilone.
BuspironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nabilone.
ButabarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nabilone.
ButacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Butacaine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Nabilone.
ButalbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butalbital.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Nabilone.
ButambenNabilone may increase the central nervous system depressant (CNS depressant) activities of Butamben.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Nabilone.
ButethalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butethal.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Nabilone.
ButorphanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nabilone.
CarbamazepineNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nabilone.
CarbinoxamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Nabilone.
CarfentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Nabilone.
CarisoprodolNabilone may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nabilone.
CeliprololNabilone may increase the tachycardic activities of Celiprolol.
CetirizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Nabilone.
Chloral hydrateNabilone may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nabilone.
ChlordiazepoxideNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nabilone.
ChlormezanoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Nabilone.
ChloroprocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nabilone.
ChlorphenamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nabilone.
ChlorphenoxamineChlorphenoxamine may increase the tachycardic activities of Nabilone.
ChlorphentermineNabilone may increase the tachycardic activities of Chlorphentermine.
ChlorpromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nabilone.
ChlorprothixeneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nabilone.
ChlorzoxazoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Nabilone.
CinchocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nabilone.
CitalopramThe risk or severity of adverse effects can be increased when Nabilone is combined with Citalopram.
ClemastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Nabilone.
ClenbuterolNabilone may increase the tachycardic activities of Clenbuterol.
ClidiniumNabilone may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Nabilone.
ClobazamNabilone may increase the central nervous system depressant (CNS depressant) activities of Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Nabilone.
clomethiazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Nabilone.
ClomipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nabilone.
ClonazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Nabilone.
ClonidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nabilone.
ClorazepateNabilone may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nabilone.
ClozapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nabilone.
CocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
CocaineCocaine may increase the tachycardic activities of Nabilone.
CodeineNabilone may increase the central nervous system depressant (CNS depressant) activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Nabilone.
CyclizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Nabilone.
CyclobenzaprineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nabilone.
CyclopentolateCyclopentolate may increase the tachycardic activities of Nabilone.
CyproheptadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Nabilone.
DantroleneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Nabilone.
DapiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nabilone.
DapoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Dapoxetine.
DarifenacinDarifenacin may increase the tachycardic activities of Nabilone.
deramciclaneNabilone may increase the central nervous system depressant (CNS depressant) activities of deramciclane.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Nabilone.
DesfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nabilone.
DesipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Nabilone.
DesloratadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
DesloratadineDesloratadine may increase the tachycardic activities of Nabilone.
DetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Detomidine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Nabilone.
DexbrompheniramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nabilone.
DexetimideDexetimide may increase the tachycardic activities of Nabilone.
DexmedetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nabilone.
DextromoramideNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Nabilone.
DextropropoxypheneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nabilone.
DezocineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Nabilone.
DiazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Nabilone.
DicyclomineDicyclomine may increase the tachycardic activities of Nabilone.
DifenoxinNabilone may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Nabilone.
DihydrocodeineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nabilone.
DihydroetorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nabilone.
DihydromorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nabilone.
DimenhydrinateNabilone may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nabilone.
DiphenhydramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nabilone.
DiphenoxylateNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nabilone.
DobutamineNabilone may increase the tachycardic activities of Dobutamine.
DopamineNabilone may increase the tachycardic activities of Dopamine.
DoramectinNabilone may increase the central nervous system depressant (CNS depressant) activities of Doramectin.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Nabilone.
DoxepinNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Nabilone.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.
DPDPENabilone may increase the central nervous system depressant (CNS depressant) activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Nabilone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.
DroperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Nabilone.
DrotebanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Nabilone.
DyclonineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nabilone.
EcgonineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Nabilone.
ECGONINE METHYL ESTERNabilone may increase the central nervous system depressant (CNS depressant) activities of ECGONINE METHYL ESTER.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Nabilone.
EfavirenzNabilone may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Nabilone.
EnfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Enflurane.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Nabilone.
EntacaponeNabilone may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Nabilone.
EphedrineNabilone may increase the tachycardic activities of Ephedrine.
EpinephrineNabilone may increase the tachycardic activities of Epinephrine.
EscitalopramThe risk or severity of adverse effects can be increased when Nabilone is combined with Escitalopram.
EstazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Nabilone.
EszopicloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nabilone.
EthanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Nabilone.
EthchlorvynolNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nabilone.
EthopropazineEthopropazine may increase the tachycardic activities of Nabilone.
EthosuximideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Nabilone.
EthotoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Nabilone.
Ethyl carbamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nabilone.
Ethyl loflazepateNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Nabilone.
EthylmorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nabilone.
EtidocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Nabilone.
EtifoxineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Nabilone.
EtilefrineNabilone may increase the tachycardic activities of Etilefrine.
EtizolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Etizolam.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Nabilone.
EtomidateNabilone may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Nabilone.
EtoperidoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Etoperidone.
EtorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Nabilone.
EzogabineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Nabilone.
FelbamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Nabilone.
FencamfamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Nabilone.
FenfluramineThe risk or severity of adverse effects can be increased when Nabilone is combined with Fenfluramine.
FenoterolNabilone may increase the tachycardic activities of Fenoterol.
FentanylNabilone may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nabilone.
FesoterodineFesoterodine may increase the tachycardic activities of Nabilone.
FexofenadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Nabilone.
FlibanserinNabilone may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Nabilone.
FludiazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nabilone.
FlunarizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Nabilone.
FlunitrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Nabilone.
FluoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Fluoxetine.
FlupentixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nabilone.
FluphenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nabilone.
FlurazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nabilone.
FluspirileneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Nabilone.
Fluticasone PropionateNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Nabilone.
FluvoxamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nabilone.
FosphenytoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Nabilone.
FospropofolNabilone may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Nabilone.
GabapentinNabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nabilone.
gabapentin enacarbilNabilone may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Nabilone.
Gallamine TriethiodideGallamine Triethiodide may increase the tachycardic activities of Nabilone.
Gamma Hydroxybutyric AcidNabilone may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Nabilone.
GlutethimideNabilone may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Nabilone.
GlycopyrroniumGlycopyrronium may increase the tachycardic activities of Nabilone.
GuanfacineNabilone may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nabilone.
HalazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Halazepam.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Nabilone.
HaloperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nabilone.
HalothaneNabilone may increase the central nervous system depressant (CNS depressant) activities of Halothane.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nabilone.
HeroinNabilone may increase the central nervous system depressant (CNS depressant) activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Nabilone.
HexamethoniumHexamethonium may increase the tachycardic activities of Nabilone.
HexobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Nabilone.
HomatropineHomatropine may increase the tachycardic activities of Nabilone.
HydrocodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nabilone.
HydromorphoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nabilone.
Hydroxyamphetamine hydrobromideNabilone may increase the tachycardic activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.
HyoscyamineHyoscyamine may increase the tachycardic activities of Nabilone.
IloperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Nabilone.
ImipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nabilone.
IndalpineThe risk or severity of adverse effects can be increased when Nabilone is combined with Indalpine.
Ipratropium bromideIpratropium bromide may increase the tachycardic activities of Nabilone.
IsofluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nabilone.
IsoprenalineNabilone may increase the tachycardic activities of Isoprenaline.
IsoxsuprineNabilone may increase the tachycardic activities of Isoxsuprine.
KetamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nabilone.
KetazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nabilone.
KetobemidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Nabilone.
LabetalolNabilone may increase the tachycardic activities of Labetalol.
LamotrigineNabilone may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nabilone.
LevetiracetamNabilone may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Nabilone.
LevobupivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nabilone.
LevocabastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Nabilone.
LevocetirizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Nabilone.
LevodopaNabilone may increase the central nervous system depressant (CNS depressant) activities of Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Nabilone.
Levomethadyl AcetateNabilone may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nabilone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Nabilone is combined with Levomilnacipran.
LevorphanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nabilone.
LidocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Nabilone.
LithiumNabilone may increase the central nervous system depressant (CNS depressant) activities of Lithium.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Nabilone.
LofentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Nabilone.
LoratadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Nabilone.
LorazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nabilone.
LoxapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nabilone.
Lu AA21004Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Nabilone.
LurasidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Nabilone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nabilone.
MaprotilineNabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nabilone.
MecamylamineMecamylamine may increase the tachycardic activities of Nabilone.
MeclizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Meclizine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Nabilone.
MedetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Nabilone.
MelatoninNabilone may increase the central nervous system depressant (CNS depressant) activities of Melatonin.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Nabilone.
MelperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Melperone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Nabilone.
MephentermineNabilone may increase the tachycardic activities of Mephentermine.
MepivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nabilone.
MeprobamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nabilone.
MesoridazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nabilone.
MetaraminolNabilone may increase the tachycardic activities of Metaraminol.
MetaxaloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Nabilone.
MethadoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Nabilone.
Methadyl AcetateNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Nabilone.
MethamphetamineNabilone may increase the tachycardic activities of Methamphetamine.
MethanthelineMethantheline may increase the tachycardic activities of Nabilone.
MethapyrileneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nabilone.
MethaqualoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Nabilone.
MethocarbamolNabilone may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nabilone.
MethohexitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Nabilone.
MethotrimeprazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Nabilone.
MethoxamineNabilone may increase the tachycardic activities of Methoxamine.
MethoxyfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nabilone.
MethsuximideNabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nabilone.
MethylphenobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nabilone.
MetixeneMetixene may increase the tachycardic activities of Nabilone.
MetyrosineNabilone may increase the sedative activities of Metyrosine.
MidazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Nabilone.
MidodrineNabilone may increase the tachycardic activities of Midodrine.
MilnacipranThe risk or severity of adverse effects can be increased when Nabilone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nabilone.
MirtazapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nabilone.
MolindoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Molindone.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Nabilone.
MorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nabilone.
N-butylscopolammonium bromideN-butylscopolammonium bromide may increase the tachycardic activities of Nabilone.
NalbuphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nabilone.
NitrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nabilone.
Nitrous oxideNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Nabilone.
NorepinephrineNabilone may increase the tachycardic activities of Norepinephrine.
NormethadoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Nabilone.
NortriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Nabilone.
NVA237NVA237 may increase the tachycardic activities of Nabilone.
NylidrinNabilone may increase the tachycardic activities of Nylidrin.
OlanzapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nabilone.
OlopatadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nabilone.
OndansetronNabilone may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Nabilone.
OpiumNabilone may increase the central nervous system depressant (CNS depressant) activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Nabilone.
OrciprenalineNabilone may increase the tachycardic activities of Orciprenaline.
OrphenadrineNabilone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineOrphenadrine may increase the tachycardic activities of Nabilone.
OsanetantNabilone may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Nabilone.
OxazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nabilone.
OxprenololNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nabilone.
OxybuprocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nabilone.
OxybutyninOxybutynin may increase the tachycardic activities of Nabilone.
OxycodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nabilone.
OxymetazolineNabilone may increase the tachycardic activities of Oxymetazoline.
OxymorphoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nabilone.
OxyphenoniumOxyphenonium may increase the tachycardic activities of Nabilone.
PaliperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nabilone.
PancuroniumPancuronium may increase the tachycardic activities of Nabilone.
ParaldehydeNabilone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Nabilone.
ParoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Paroxetine.
PentazocineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nabilone.
PentobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nabilone.
PentoliniumPentolinium may increase the tachycardic activities of Nabilone.
PerampanelNabilone may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Nabilone.
PerospironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Perospirone.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Nabilone.
PerphenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nabilone.
PethidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nabilone.
PhenmetrazineNabilone may increase the tachycardic activities of Phenmetrazine.
PhenobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nabilone.
PhenoxyethanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Nabilone.
PhentermineNabilone may increase the tachycardic activities of Phentermine.
PhenylephrineNabilone may increase the tachycardic activities of Phenylephrine.
PhenylpropanolamineNabilone may increase the tachycardic activities of Phenylpropanolamine.
PhenytoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Nabilone.
PimozideNabilone may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Nabilone.
PipamperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nabilone.
PipecuroniumPipecuronium may increase the tachycardic activities of Nabilone.
PipotiazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Nabilone.
PirenzepinePirenzepine may increase the tachycardic activities of Nabilone.
PizotifenNabilone may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Nabilone.
PomalidomideNabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Nabilone.
PramipexoleNabilone may increase the sedative activities of Pramipexole.
PramocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Nabilone.
PrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Nabilone.
PregabalinNabilone may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nabilone.
PrilocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Nabilone.
PrimidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Nabilone.
ProcaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Procaine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Nabilone.
ProcaterolNabilone may increase the tachycardic activities of Procaterol.
ProchlorperazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nabilone.
ProcyclidineProcyclidine may increase the tachycardic activities of Nabilone.
PromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Promazine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Nabilone.
PromethazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Nabilone.
PropanthelinePropantheline may increase the tachycardic activities of Nabilone.
ProparacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nabilone.
PropofolNabilone may increase the central nervous system depressant (CNS depressant) activities of Propofol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nabilone.
PropoxycaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Nabilone.
ProtriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nabilone.
PSD502Nabilone may increase the central nervous system depressant (CNS depressant) activities of PSD502.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Nabilone.
PseudoephedrineNabilone may increase the tachycardic activities of Pseudoephedrine.
QuazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Nabilone.
QuetiapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nabilone.
QuinidineQuinidine may increase the tachycardic activities of Nabilone.
RacepinephrineNabilone may increase the tachycardic activities of Racepinephrine.
RamelteonNabilone may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Nabilone.
RemifentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nabilone.
RemoxiprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nabilone.
ReserpineNabilone may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nabilone.
RisperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Nabilone.
RitodrineNabilone may increase the tachycardic activities of Ritodrine.
RomifidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Romifidine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Nabilone.
RopiniroleNabilone may increase the sedative activities of Ropinirole.
RopivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nabilone.
RotigotineNabilone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nabilone.
S-EthylisothioureaNabilone may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nabilone.
ScopolamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
ScopolamineScopolamine may increase the tachycardic activities of Nabilone.
Scopolamine butylbromideScopolamine butylbromide may increase the tachycardic activities of Nabilone.
SecobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nabilone.
SertindoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Nabilone.
SertralineThe risk or severity of adverse effects can be increased when Nabilone is combined with Sertraline.
SevofluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nabilone.
Sodium oxybateNabilone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Nabilone.
SolifenacinSolifenacin may increase the tachycardic activities of Nabilone.
StiripentolNabilone may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Nabilone.
SufentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nabilone.
SulpirideNabilone may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nabilone.
SuvorexantNabilone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Nabilone.
SynephrineNabilone may increase the tachycardic activities of Synephrine.
TapentadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Nabilone.
TasimelteonNabilone may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Nabilone.
TemazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nabilone.
TerbutalineNabilone may increase the tachycardic activities of Terbutaline.
TetrabenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Nabilone.
TetracaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Nabilone.
TetrodotoxinNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Nabilone.
TetryzolineNabilone may increase the tachycardic activities of Tetryzoline.
ThalidomideNabilone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nabilone.
ThiamylalNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nabilone.
ThiopentalNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Nabilone.
ThioridazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nabilone.
ThiothixeneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Nabilone.
TiagabineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Nabilone.
TiletamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Nabilone.
TiotropiumTiotropium may increase the tachycardic activities of Nabilone.
TizanidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nabilone.
TolcaponeNabilone may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nabilone.
TolterodineTolterodine may increase the tachycardic activities of Nabilone.
TopiramateNabilone may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Nabilone.
TramadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Nabilone.
Trans-2-PhenylcyclopropylamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Nabilone.
TranylcypromineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nabilone.
TrazodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Nabilone.
TriazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Nabilone.
TrifluoperazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nabilone.
TriflupromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nabilone.
TrihexyphenidylTrihexyphenidyl may increase the tachycardic activities of Nabilone.
TrimethaphanTrimethaphan may increase the tachycardic activities of Nabilone.
TrimipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Nabilone.
TriprolidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Nabilone.
TropicamideTropicamide may increase the tachycardic activities of Nabilone.
TrospiumTrospium may increase the tachycardic activities of Nabilone.
TubocurarineTubocurarine may increase the tachycardic activities of Nabilone.
TyramineNabilone may increase the tachycardic activities of Tyramine.
UmeclidiniumUmeclidinium may increase the tachycardic activities of Nabilone.
Valproic AcidNabilone may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Nabilone.
VecuroniumVecuronium may increase the tachycardic activities of Nabilone.
VigabatrinNabilone may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Nabilone.
VilazodoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Vilazodone.
VortioxetineNabilone may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Nabilone.
XylazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Xylazine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Nabilone.
YohimbineThe therapeutic efficacy of Nabilone can be decreased when used in combination with Yohimbine.
ZaleplonNabilone may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nabilone.
ZiconotideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Nabilone.
ZimelidineThe risk or severity of adverse effects can be increased when Nabilone is combined with Zimelidine.
ZiprasidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Nabilone.
ZolazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Nabilone.
ZolpidemNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nabilone.
ZonisamideNabilone may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Nabilone.
ZopicloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Nabilone.
ZotepineNabilone may increase the central nervous system depressant (CNS depressant) activities of Zotepine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Nabilone.
ZuclopenthixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nabilone.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Cannabinoid receptor activity
Specific Function:
Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis.
Gene Name:
CNR2
Uniprot ID:
P34972
Molecular Weight:
39680.275 Da
References
  1. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G: Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002 Jan;135(1):181-7. [PubMed:11786493 ]
  2. Mendizabal VE, Adler-Graschinsky E: Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol. 2007 Jun;151(4):427-40. Epub 2007 Apr 23. [PubMed:17450170 ]
  3. Davis M, Maida V, Daeninck P, Pergolizzi J: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. [PubMed:17139494 ]
  4. Kraft B, Kress HG: [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz. 2004 Jun;18(3):203-10. [PubMed:15221424 ]
  5. Darmani NA: The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001 Oct 26;430(1):49-58. [PubMed:11698062 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Drug binding
Specific Function:
Involved in cannabinoid-induced CNS effects. Acts by inhibiting adenylate cyclase. Could be a receptor for anandamide. Inhibits L-type Ca(2+) channel current. Isoform 2 and isoform 3 have altered ligand binding.
Gene Name:
CNR1
Uniprot ID:
P21554
Molecular Weight:
52857.365 Da
References
  1. Davis M, Maida V, Daeninck P, Pergolizzi J: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. [PubMed:17139494 ]
  2. Darmani NA: The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001 Oct 26;430(1):49-58. [PubMed:11698062 ]
  3. Hirst RA, Almond SL, Lambert DG: Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neurosci Lett. 1996 Dec 13;220(2):101-4. [PubMed:8981483 ]
  4. Pertwee RG: Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. 1999 Oct;6 Suppl 3:12-5. [PubMed:10575283 ]
  5. Pertwee RG, Fernando SR: Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol. 1996 Aug;118(8):2053-8. [PubMed:8864542 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23